NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock - Currency: USD
1.75
-0.25 (-12.5%)
The current stock price of CYCC is 1.75 USD. In the past month the price decreased by -51.52%. In the past year, price decreased by -94.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18 | 327.00B | ||
AMGN | AMGEN INC | 13.25 | 147.86B | ||
GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 21.01B | ||
BIIB | BIOGEN INC | 8.25 | 19.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
CYCLACEL PHARMACEUTICALS INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Phone: 19085177330
The current stock price of CYCC is 1.75 USD. The price decreased by -12.5% in the last trading session.
The exchange symbol of CYCLACEL PHARMACEUTICALS INC is CYCC and it is listed on the Nasdaq exchange.
CYCC stock is listed on the Nasdaq exchange.
CYCLACEL PHARMACEUTICALS INC (CYCC) has a market capitalization of 667.10M USD. This makes CYCC a Small Cap stock.
CYCLACEL PHARMACEUTICALS INC (CYCC) currently has 12 employees.
The Revenue of CYCLACEL PHARMACEUTICALS INC (CYCC) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the CYCC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYCC does not pay a dividend.
CYCLACEL PHARMACEUTICALS INC (CYCC) will report earnings on 2025-08-12.
CYCLACEL PHARMACEUTICALS INC (CYCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.49).
The outstanding short interest for CYCLACEL PHARMACEUTICALS INC (CYCC) is 1.45% of its float. Check the ownership tab for more information on the CYCC short interest.
ChartMill assigns a fundamental rating of 1 / 10 to CYCC. CYCC may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CYCC reported a non-GAAP Earnings per Share(EPS) of -3.49. The EPS increased by 75.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -273.86% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to CYCC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCC